Disease-modifying agents in multiple sclerosis

Annals of Indian Academy of Neurology

Volumn 12, Issue 4, 2009, Pages 273-282

  Coyle, P K ^a  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Disease modifying agents; Glatiramer acetate; Interferon beta; Multiple sclerosis therapy; Natalizumab

Indexed keywords

ANTIEMETIC AGENT; ANTIINFECTIVE AGENT; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CNEDIONE; CYCLOPHOSPHAMIDE; EXTAVIA; FOLINATE CALCIUM; GLATIRAMER; GLUCOCORTICOID; IBUPROFEN; IMMUNOGLOBULIN; INTERFERON BETA SERINE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; NATALIZUMAB; PLACEBO; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANAPHYLAXIS; ANEMIA; ARTHRALGIA; AVASCULAR NECROSIS; BEDTIME DOSAGE; BLADDER DYSFUNCTION; BLOOD CELL COUNT; BONE DISEASE; BONE MARROW TRANSPLANTATION; CARDIOMYOPATHY; CATARACT; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONVENIENCE SAMPLE; DEPRESSION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ERYTHROCYTE; FATIGUE; FIBROSIS; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEADACHE; HEMORRHAGIC CYSTITIS; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPOTENSION; IMMUNOMODULATION; INFECTION; INFERTILITY; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; LEUKEMIA; LEUKOCYTE; LEUKOPENIA; LIFESTYLE; LIPOATROPHY; MENSTRUATION DISORDER; META ANALYSIS; MONOTHERAPY; MOOD DISORDER; MULTIPLE SCLEROSIS; MYALGIA; MYOPATHY; NAUSEA; NEUROIMAGING; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT ATTITUDE; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PLASMAPHERESIS; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RELAPSE; REVIEW; SIDE EFFECT; SKIN DIMPLING; SLEEP DISORDER; STRIA; SYSTEMATIC REVIEW; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THYROID FUNCTION; TREATMENT RESPONSE; TREMOR; URTICARIA; WEIGHT GAIN;

EID: 72949091421     PISSN: 09722327     EISSN: 19983549     Source Type: Journal    
DOI: 10.4103/0972-2327.58280     Document Type: Review

References (73)

1. IFNB Multiple Sclerosis Study Group. Inteferon beta-1b is effective in relapsing remitting multiple sclerosis: I: Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667
2. Paty DW, Li DK; UBC MS/MRI Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II: MRI analysis results of a multi-center, randomized, double-blind, placebocontrolled trial. Neurology 1993;43:662-667
3. IFNβ Multiple Sclerosis Study Group; University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1996;45:1277-1285
4. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276
5. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta 1-a for disease progression in relapsing multiple sclerosis: The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294
6. PRISMS (Prevention of Relapses and Disability by interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind placebo controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504
7. Li DK, Paty DW; UBC MS/MRI analysis research group and PRISMS study group. Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon fl1a in relapsing remitting multiple sclerosis. Ann Neurol 1999;46:197-206.
8. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, et al. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double blind, randomized, multicenter trial. Lancet 2002;360:2018-2025
9. Krapf H, Morrissey SP, Zenker O, Zwingers T, Gonsette R, Hartung HP; et al. Effect of mitoxantrone on MRI in progressive MS: Results of the MIMS trial. Neurology 2005;65:690-695
10. Polman CH, O.Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
11. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-923
12. Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, et al. How effective are disease-modifying drugs in delaying progression in relapsing onset MS? Neurology 2007;69:1498-1507
13. Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, et al. New natural history of interferon--treated relapsing multiple sclerosis. Ann Neurol 2007;61:300-306
14. Yong VW, Chabot S. Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998;51:689-692
15. Goodin DS, Frohman EM, Hurwitz B, O'Connor PW, Oger JJ, Reder AT, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007;68:977-984 (Pubitemid 46569129)
16. Sorensen PS, Deisenhammer F, Duda P, Hohlfeld R, Myhr KM, Palace J, et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: Report of an EFNS task force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005;12:817-827
17. Hesse D, Sellebjerg F, Sorensen PS. Absence of MxA induction by interferon fl in patients with MS refl ects complete loss of bioactivity. Neurology 2009;73:372-377
18. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BG, Burks JS. Management of patients receiving interferon beta-1b for multiple sclerosis: Report of a consensus conference. Neurology 1996;46:12-18
19. Walther EU, Hohlfeld R. Multiple sclerosis side effects of interferon beta therapy and their management. Neurology 1999;53:1622-1627
20. European Study Group on Interferon--1b in Secondary Progressive MS. Placebo-controlled multicenter randomized trial of interferon--1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-1497
21. Panitch H, Miller A, Paty D, Weinshenker B; North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS. Neurology 2004;63:1788-1795
22. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, et al. Treatment with interferon beta-1b delays conversion to clinical definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-1249
23. Kappos L, Weinshenker B, Pozzilli C, Thompson AJ, Dahlke F, Beckmann K, et al. Interferon beta-1b in secondary progressive MS: A combined analysis of the two trials. Neurology 2004;63:1779-1787
24. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127
25. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a First clinical event suggestive of multiple sclerosis: A 3 year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-397
26. Freedman MS, Kappos L, Polman CH, et al. Impact of early Interferon beta-1b treatment on disease evaluation over 5 years in patients with a first event suggestive of Multiple Sclerosis. World Congress on Treatment and Research in Multiple Sclerosis 2008.
27. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
28. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002;59:679-687
29. PRISMS Study Group, University of British Columbia MS/MRI Analysis Group PRISMS-4: Long-term efficacy of interferon β-1a in relapsing MS. Neurology 2001;56:1628-1636
30. Comi G, Frippi M, Barkhoff F, Durelli L, Edan G, Fernández O, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomized study. Lancet 2001;357:1576-1582
31. Secondary Progressive Efficacy Clinical Trial of Recombinant 1-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-Beta-1a in secondary progressive MS. Clinical Results. Neurology 2001;56:1496-1504
32. Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H, Drexler E, et al. A pilot trial of Cop-1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987;317:404-414
33. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001;49:290-297
34. Comi G, Martinelli V, Rodegher M et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised,double-blind, placebo-controlled trial. LANCET: 2009;374:1503-1511
35. Wolinsky JS, Narayana PA, O.Connor P, Coyle PK, Ford C, Johnson K, et al. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, doubleblind, placebo-controlled trial. Ann Neurol 2007;61:14-24.
36. Coyle PK, Foley JF, Fox E, et al. Best Practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy. Mult Scler 2009 (in press).
37. Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomized multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112-118
38. Panitch HS, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, et al. Randomized, comparative study of interferon fl1-a treatment regimens in MS: The EVIDENCE trial. Neurology 2002;59:1496-1506
39. Panitch H, Goodin D, Francis G, Chang P, Coyle P, O'Connor P, et al. Benefits of high-dose, high-frequency interferon beta-1a in relapsing remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial. J Neurol Sci 2005;239:67-74.
40. Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, et al. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: The EVIDENCE Study. Arch Neurol 2005;62:785-792
41. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, et al. Every other day interferon beta-1b vs once -weekly interferon beta-1a for multiple sclerosis: Results of a 2-year prospective randomized multicenter study (INCOMIN). Lancet 2002;359:1453-1460
42. Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomized, parallel, open-label trial. Lancet Neurol 2008;7:903-914
43. O.Connor P, Filippi M, Arnason B. 250 mcg or 5 mcg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: A prospective, randomised multicentre study. Lancet Neurol 2009;10:889-897
44. Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. Cochrane Database Syst Rev 2007;4:CD003982.
45. Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, et al. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult Scler 2009;15:965-976
46. La Mantia L, Mascoli N, Milanese C. Azathioprine: Safety profile in multiple sclerosis patients. Neurol Sci 2007;28:299-303.
47. Atkins H, Freedman M. Immunoablative therapy as a treatment for aggressive multiple sclerosis. Neurol Clin 2005;23:273-300.
48. Fassas A, Mancardi GL. Autologous hemopoietic stem cell transplantation for multiple sclerosis: Is it worthwhile? Autoimmunity 2008;1 in press.
49. Mondria T, Lamers CH, te Boekhorst PA, Gratama JW, Hintzen RQ. Bone-marrow transplantation fails to halt intrathecal lymphocyte activation in multiple sclerosis. Neurol Neurosurg Psychiatry 2008;79:1013-1015
50. Makhani N, Gorman MP, Branson HM, Stazzone L, Banwell BL, Chitnis T. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology 2009;72:2076-2082
51. Gladstone, DE, Zamkoff KW, Krupp L, Peyster R, Sibony P, Christodoulou C, et al. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol 2006;63:1388-1393
52. Krishnan C, Kaplin AI, Brodsky RA, Drachman DB, Jones RJ, Pham DL, et al. Reduction of disease activity and disability with high dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol 2008;65:1044-1051
53. Schwartzman RJ, Simpkins N, Alexander GM, Reichenberger E, Ward K, Lindenberg N, et al. High dose cyclophosphamide in the treatment of multiple sclerosis. CNS Neurosci Ther 2009;15:118-127
54. Gray Q, McDonnell GV, Forbes RB. Methotrexate for multiple sclerosis. Cochrane Database Syst Rev 2004;2:CD003208.
55. Gray OM, McDonnell GV, Forbes RB. A systematic review of oral methotrexate for multiple sclerosis. Mult Scler 2006;12:507-510
56. Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Van Dyke C. Low-dose oral methotrexate in chronic progressive multiple sclerosis: Analyses of serial MRIs. Neurology 1996;47:1153-1157
57. Calabresi PA, Wilterdink JL, Rogg JM, Mills P, Webb A, Whartenby KA. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 2002;2:314-317
58. Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL 3rd, et al. Results of the Avonex combination trial (ACT) in relapsing-remitting MS. Neurology 2009;72:535-541
59. Lugaresi A, Caporale C, Farina D, Marzoli F, Bonanni L, Muraro PA, et al. Low-dose oral methotrexate treatment in chronic progressive multiple sclerosis. Neurol Sci 2001;22:209-210
60. Rowe VD, Dressman LA, Wang D. High dose intravenous methotrexate in MS patients worsening despite Avonex therapy: Final results. Neurology 2004;62:260-261
61. Frohman EM, Brannon K, Racke MK, Hawker K. Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol 2004;27:80-83
62. Vermersch P, Waucquier N, Michelin E, Bourteel H, Stojkovic T, Ferriby D, et al. Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis. Eur J Neurol 2007;1:85-89
63. Multiple Sclerosis Therapy Consensus Group (MSTCG), Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations. J Neurol 2008;255:1449-1463
64. Alam SM, Kyriakides T, Lawden M, Newman PK. Methylprednisolone in multiple sclerosis: A comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 1993;56:1219-1220
65. Barnes D, Hughes RA, Morris RW, Wade-Jones O, Brown P, Britton T, et al. Randomized trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997;349:902-906 (Pubitemid 27139818)
66. Burton JM, O.Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2009;3:CD006921.
67. Goodkin DE, Kinkel RP, Weinstock-Guttman B, VanderBrug-Medendorp S, Secic M, Gogol D, et al. A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis. Neurology 1998;51:239 45.
68. Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, et al. Effects of IV methylprednisolone on brain atrophy in relapsing remitting MS. Neurology 57:1239-1247
69. Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, et al. NORdic trial of oral Methylprednisolone as add-on therapy to interferon beta-1a for treatment of relapsing-remitting multiple sclerosis (NORMIMS study): A randomized, placebo-controlled trial. Lancet Neurol 2009;6:519-529
70. Hommes OR, Sorensen PS, Fazekas F, Enriquez MM, Koelmel HW, Fernandez O, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: Randomised placebo-controlled trial. Lancet 2004;364:1149-1156
71. Elovaara I, Apostolski S, van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008;15:893-908.
72. Tumani H. Corticosteroids and plasma exchange in multiple sclerosis. J Neurol 2008;255:36-42.
73. Trebst C, Reising A, Kielstein JT, Hafer C, Stangel M. Plasma exchange therapy in steroid-unresponsive relapses in patients with multiple sclerosis. Blood Purif 2009;28:108-115